11172017Headline:

Philadelphia, Pennsylvania

HomePennsylvaniaPhiladelphia

Email Jamie Sheller
Jamie Sheller
Jamie Sheller
Attorney • (800) 883-2299

Gynocological Cancer After Laparoscopic Power Morcellator Procedure for Uterine Fibriods

Comments Off

If You or someone you know has been diagnosed with leiomyosarcoma cancer (cancerous uterine fibroids), a gynecologic cancer or occult malignancy (a cancer from an unknown source) following a gynecological surgery such as a hysterectomy or myomectomy that used a laproscopic power morcellator, you may have a claim.
Laparoscopic Power Morcellator (LPM)-Surgeons began using LPMs in the mid-1990s as an alternative to more invasive procedures used to remove uterine fibroids during either a myomectomy or a hysterectomy. An LPM procedure involves the use of a thin, lighted tube equipped with a camera called a laparoscope and a power morcellator, which uses a small blade inside of a hollow cylinder to fragment and remove the specimen through the tube. A special report released by the American College of Obstetricians and Gynecologists (ACOG) in May 2014 estimates that, of the approximately 600,000 hysterectomies done in the U.S. each year:

• <30 percent are performed laparoscopically in women
younger than 40
• <44 percent in women ages 40 to 49, and;
• 16 percent in women ages 50 to 59.

It adds that “the most common indication for hysterectomy is uterine leiomyomas [uterine fibroids], accounting for an estimated 40% of hysterectomies.”According to the FDA, an estimated 1 in 350 women receiving either a hysterectomy or myomectomy will have an unsuspected uterine sarcoma (cancerous uterine fibroids).The potential spread of cancerous tissue due to LPM. Please contact attorney Jamie Sheller if you or a loved one has suffer this type of injury following use of LPM.